Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
作者： Maria Paola Martelli , Ilaria Gionfriddo , Federica Mezzasoma , Francesca Milano , Sara Pierangeli
DOI: 10.1182/BLOOD-2014-11-611459
关键词:
摘要: Nucleophosmin (NPM1) mutations represent an attractive therapeutic target in acute myeloid leukemia (AML) because they are common (∼30% AML), stable, and behave as a founder …
ashpublications.org
unipg.it
bloodjournal.org参考文章(40)
Meir Wetzler, Chris Andrews, Laurie A. Ford, Sheila Tighe, Maurice Barcos, Sheila N. J. Sait, AnneMarie W. Block, Norma J. Nowak, Maria R. Baer, Eunice S. Wang, Heinz Baumann, Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia† Cancer. ,vol. 117, pp. 4831- 4868 ,(2011) , 10.1002/CNCR.26097
Sha Yi, Lu Wen, Jing He, Youping Wang, Fei Zhao, Jie Zhao, Zichu Zhao, Guohui Cui, Yan Chen, Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation. Annals of Hematology. ,vol. 94, pp. 201- 210 ,(2015) , 10.1007/S00277-014-2206-X
J. Zhu, M. H. M. Koken, F. Quignon, M. K. Chelbi-Alix, L. Degos, Z. Y. Wang, Z. Chen, H. de The, Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia Proceedings of the National Academy of Sciences of the United States of America. ,vol. 94, pp. 3978- 3983 ,(1997) , 10.1073/PNAS.94.8.3978
Gail J. Roboz, Ellen K. Ritchie, Tania Curcio, Juliette Provenzano, Rebecca Carlin, Michael Samuel, Beth Wittenberg, Madhu Mazumdar, Paul J. Christos, Susan Mathew, Sandra Allen-Bard, Eric J. Feldman, Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia Cancer. ,vol. 113, pp. 2504- 2511 ,(2008) , 10.1002/CNCR.23855
Dennis J. Goussetis, Elias Gounaris, Edward J. Wu, Eliza Vakana, Bhumika Sharma, Matthew Bogyo, Jessica K. Altman, Leonidas C. Platanias, Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. ,vol. 120, pp. 3555- 3562 ,(2012) , 10.1182/BLOOD-2012-01-402578
Lingyan Wang, Buyuan Chen, Minhui Lin, Yanqin Cao, Yingyu Chen, Xinji Chen, Tingbo Liu, Jianda Hu, Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling. Immunobiology. ,vol. 220, pp. 331- 340 ,(2015) , 10.1016/J.IMBIO.2014.10.015
Robert E. Gallagher, Dueling mutations in normal karyotype AML Blood. ,vol. 106, pp. 3681- 3682 ,(2005) , 10.1182/BLOOD-2005-08-3444
Hyman M. Schipper, Samuel Waxman, Wilson H. Miller, Jack Singer, Janet S. Lee, Mechanisms of action of arsenic trioxide. Cancer Research. ,vol. 62, pp. 3893- 3903 ,(2002)
E Tiacci, A Spanhol-Rosseto, M P Martelli, L Pasqualucci, H Quentmeier, V Grossmann, H G Drexler, B Falini, The NPM1 wild-type OCI-AML2 and the NPM1 -mutated OCI-AML3 cell lines carry DNMT3A mutations Leukemia. ,vol. 26, pp. 554- 557 ,(2012) , 10.1038/LEU.2011.238
Maria Paola Martelli, Valentina Pettirossi, Christian Thiede, Elisabetta Bonifacio, Federica Mezzasoma, Debora Cecchini, Roberta Pacini, Alessia Tabarrini, Raffaella Ciurnelli, Ilaria Gionfriddo, Nicla Manes, Roberta Rossi, Linda Giunchi, Uta Oelschlägel, Lorenzo Brunetti, Marica Gemei, Mario Delia, Giorgina Specchia, Arcangelo Liso, Mauro Di Ianni, Francesco Di Raimondo, Franca Falzetti, Luigi Del Vecchio, Massimo F. Martelli, Brunangelo Falini, CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice Blood. ,vol. 116, pp. 3907- 3922 ,(2010) , 10.1182/BLOOD-2009-08-238899